Sagimet Biosciences Inc. (SGMT)
(Delayed Data from NSDQ)
$8.96 USD
+0.51 (6.04%)
Updated Aug 5, 2025 04:00 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
SGMT 8.96 +0.51(6.04%)
Will SGMT be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for SGMT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SGMT
What Makes Sagimet Biosciences Inc. (SGMT) a Strong Momentum Stock: Buy Now?
Wall Street Analysts Predict a 437.05% Upside in Sagimet Biosciences Inc. (SGMT): Here's What You Should Know
SGMT: What are Zacks experts saying now?
Zacks Private Portfolio Services
SGMT Stock Up 12.6% on FDA Fast Track for Liver Disease Drug
Other News for SGMT
Sagimet Biosciences to Participate in the Canaccord Genuity 45th Annual Growth Conference | ...
Sagimet Biosciences (SGMT) Gains on Canaccord Genuity's Positive Outlook
Sagimet gains as Canaccord Genuity starts with Buy on potential against MASH
This Sarepta Therapeutics Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Thursday
Sagimet Biosciences (SGMT) Receives 'Buy' Rating from Canaccord Genuity | SGMT Stock News